Bone health in prostate cancer patients receiving androgen-deprivation therapy: the role of bisphosphonates.

Published

Journal Article (Review)

Androgen-deprivation therapy, a mainstay in the treatment of locally advanced and metastatic prostate cancer, is associated with significant bone loss and related complications, such as fracture. Bisphosphonates, osteoclast inhibitors, are effective in preventing skeletal-related events in patients with metastatic prostate cancer and also in preventing bone loss in patients with locally advanced disease. Understanding the management of bone health, including identifying patients at risk, the most appropriate therapy, and monitoring and managing side effects, is critical. This review provides the most recent bone health risk factor and bisphosphonate data available for prostate cancer patients.

Full Text

Duke Authors

Cited Authors

  • Polascik, TJ

Published Date

  • 2008

Published In

Volume / Issue

  • 11 / 1

Start / End Page

  • 13 - 19

PubMed ID

  • 17923854

Pubmed Central ID

  • 17923854

Electronic International Standard Serial Number (EISSN)

  • 1476-5608

Digital Object Identifier (DOI)

  • 10.1038/sj.pcan.4501019

Language

  • eng

Conference Location

  • England